Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.
What happened
FDA inspected Omega Tech Labs' Boise facility from January 17 to 22, 2024, and found the firm released and distributed multiple batches of a combination drug-device product that exceeded total aerobic plate count limits; the firm delayed shipment and kept testing until preservatives lowered the counts. FDA also found the water system repeatedly exceeded microbial limits, the contamination source was not identified, and the firm had raw-material, stability, cleaning-validation, process-validation, and quality-unit failures; FDA said it had not received a response to the Form FDA 483 (inspection observations). FDA also collected labels for a product it determined was an unapproved new drug.
What FDA found
Omega Tech Labs released and distributed batches of its combination product that exceeded total aerobic plate count limits and used preservatives to lower microbial counts instead of preventing contamination.
21 CFR 211.113(a)The firm lacked adequate production and process-control procedures and did not validate its manufacturing process, qualify equipment, or adequately qualify and maintain its water system; cleaning validation was not updated for the new product.
21 CFR 211.100(a)The firm released glycerin based on a supplier's certificate of analysis without validating the supplier's results and did not test each incoming component lot for identity and conformity with specifications.
21 CFR 211.84(d)(1) and (d)(2)The firm did not have adequate stability data or a sufficient stability testing program to show the product remained acceptable through its labeled expiry.
21 CFR 211.166(a)The quality control unit did not record deviations, investigate out-of-limit microbial results, or establish appropriate specifications for impurities and objectionable organisms.
21 CFR 211.22FDA collected labels for a product it determined was an unapproved new drug that cannot be introduced into interstate commerce.
FD&C Act section 505(a), 21 U.S.C. 355(a)
What FDA wants
FDA tells Omega Tech Labs to respond in writing within 15 working days with the actions taken to correct the violations and prevent recurrence, including independent assessments, risk assessments, investigations, and testing. It also requires DEG (diethylene glycol) and EG (ethylene glycol) test results for reserve samples of high-risk components within 30 calendar days.
Who should pay attention
- brands that contract with Omega Tech Labs to make their combination products
- patients or users of the affected combination product
- companies using glycerin or other high-risk components from similar suppliers
This is a summary. Read the original letter on fda.gov.